CLAIMS

1. A method for treating systemic lupus erythematosus (SLE), comprising administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical preparation of a recombinant TACI-Fc fusion protein in a dose of 80-240 mg per administration, wherein the recombinant TACI-Fc fusion protein has a sequence as shown in SEQ ID NO: 1, and the subject has moderate to severe SLE prior to receiving the pharmaceutical preparation.

2. Use of a therapeutically effective amount of a pharmaceutical preparation of a recombinant TACI-Fc fusion protein in a dose of 80-240 mg per administration, in the manufacture of a medicament for the treatment of moderate to severe systemic lupus erythematosus (SLE), wherein the recombinant TACI-Fc fusion protein has a sequence as shown in SEQ ID NO: 1.

3. The method of claim 1 or the use of claim 2, wherein the dose is 80 mg, 85 mg, 90 mg, 95 mg, 100 mg, 105 mg, 110 mg, 115 mg, 120 mg, 125 mg, 130 mg, 135 mg, 140 mg, 145 mg, 150 mg, 155 mg, 160 mg, 165 mg, 170 mg, 175 mg, 180 mg, 190 mg, 195 mg, 200 mg, 205 mg, 210 mg, 215 mg, 220 mg, 225 mg, 230 mg, 235 mg, or 240 mg per administration.

4. The method of claims 1 or 3, or the use of claims 2 or 3, wherein the dose is 80 mg, 160mg or 240mg per administration.

5. The method of any one of claims 1, 3 or 4, or the use of any one of claims 2 to 4, comprising administering the subject in need thereof once every week, every two weeks, every three weeks, or every four weeks.

6. The method or the use of claim 5, comprising administering the subject in need thereof

once every week.

7. The method or the use of any one of claims 3 to 6, wherein the pharmaceutical preparation is a lyophilized preparation or a liquid preparation.

8. The method or the use of claim 7, wherein the pharmaceutical preparation is a lyophilized preparation.

9. The method or the use of claim 7, wherein the pharmaceutical preparation is administered by subcutaneous injection, intraperitoneal injection, intramuscular injection, or intravenous injection.

10. The method or the use of claim 9, wherein the pharmaceutical preparation is administered by subcutaneous injection.

11. The method or the use of any one of claims 3 to 6, 8 or 10, wherein the pharmaceutical preparation is administered to the subject in need thereof for consecutive 12 weeks, 24 weeks, 36 weeks, 48 weeks, 60 weeks, 72 weeks or more.

12. The method or the use of claim 11, wherein the pharmaceutical preparation is administered to the subject in need thereof for consecutive 48 weeks or longer.

13. The method of any one of claims 1 or 3 to 12, or the use of any one of claims 2 to 12, wherein two of the recombinant TACI-Fc fusion proteins form a double-stranded structure through interchain disulfide bond formed in Fc hinge region in a liquid pharmaceutical preparation.